RedHill Biopharma
8045 Arco Corporate Drive
Suite 200
Raleigh
NC
27617
United States
Website: http://www.redhillbio.com/
477 articles about RedHill Biopharma
-
RedHill Biopharma Ltd. Announces Collaboration with Germany’s Fraunhofer Institute For Oncology Drug RP101
2/8/2016
-
RedHill Biopharma Ltd. Announces Passing Of Board Member Alicia Rotbard
11/30/2015
-
RedHill Biopharma Ltd. Announces Completion Of Dosing In Phase IIa Study Of RHB-104 For Multiple Sclerosis
11/30/2015
-
RedHill Biopharma Ltd. To Present At The Jefferies Autumn 2015 Global Healthcare Conference
11/12/2015
-
RedHill Biopharma Ltd. Reports Results For The Third Quarter Of 2015
11/9/2015
-
RedHill Biopharma Ltd. And IntelGenx Corp. Announce First European Marketing Approval Of RIZAPORT (RHB-103) For Migraines
11/9/2015
-
RedHill Biopharma Ltd. To Host Third Quarter 2015 Financial Results Conference Call On November 9, 2015
10/29/2015
-
RedHill Biopharma Ltd. To Present At The BIO-Europe 2015 Conference
10/28/2015
-
RedHill Biopharma Ltd. Announces Positive Top-Line Results From YELIVA (ABC294640) Phase I Study In Advanced Solid Tumors
10/26/2015
-
RedHill Biopharma Ltd. To Present At Gelbart-Kahana Biomed Conference On October 25, 2015
10/22/2015
-
RedHill Biopharma Ltd. Announces Planned Management Changes
10/22/2015
-
RedHill Biopharma Ltd. Announces National Cancer Institute Grant Awarded To Apogee Biotechnology Corp. For YELIVA (ABC294640) Prostate Cancer Research
10/22/2015
-
RedHill Biopharma Ltd. To Present At The BioNetwork West Partnering Summit
10/19/2015
-
RedHill Biopharma Ltd. And IntelGenx Corp. Announce RIZAPORT (RHB-103) Marketing Authorization Application Is Approvable Under The European Decentralized Procedure
9/10/2015
-
RedHill Biopharma Ltd. Announces $2 Million National Cancer Institute Grant For YELIVA(TM) (ABC294640) Phase II Study For Multiple Myeloma
9/9/2015
-
RedHill Biopharma Ltd. Announces Standard-Of-Care Eradication Data From The RHB-105 Phase III Study Further Supporting The Study's Positive Results
9/8/2015
-
RedHill Biopharma Ltd. To Present At The Rodman & Renshaw 17th Annual Global Investment Conference
9/2/2015
-
RedHill Biopharma Ltd. Announces Last Patient Visit In The Phase I Study With YELIVA (ABC294640) For Advanced Solid Tumors
9/1/2015
-
RedHill Biopharma Ltd. Receives Notice Of Allowance For New Israeli Patent Covering RHB-104 For The Treatment Of Crohn's Disease
8/27/2015
-
Recipharm AB Signs Agreement With RedHill Biopharma Ltd. For Manufacturing Of RHB-105 For Treatment Of H. Pylori Infection
8/26/2015